Tags

Type your tag names separated by a space and hit enter

Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report.
Asia Pac J Clin Oncol. 2019 Oct; 15 Suppl 6:5-7.AP

Abstract

Advanced non-small cell lung cancer (NSCLC) with leptomeningeal metastases (LM) is associated with a dismal prognosis of typically 3-9 months. In preclinical and clinical studies, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib has demonstrated activity in the central nervous system (CNS), and studies are ongoing. We report here a case of osimertinib used at 160 mg once daily in a heavily pretreated patient with EGFR exon 20 T790M-negative advanced NSCLC with LM to achieve a partial response, including shrinkage of the LM, for up to 12 months until further progression. The case suggests the feasibility of using osimertinib at a twofold standard dose to treat CNS metastases, irrespective of the T790M mutation status.

Authors+Show Affiliations

Hong Kong Adventist Oncology Center, Hong Kong Adventist Hospital, Stubbs Road, Hong Kong.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

31642175

Citation

Tsang, Maverick Wai-Kong. "Osimertinib 160 Mg Daily for Advanced Non-small Cell Lung Cancer With Leptomeningeal Metastasis: a Case Report." Asia-Pacific Journal of Clinical Oncology, vol. 15 Suppl 6, 2019, pp. 5-7.
Tsang MW. Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report. Asia Pac J Clin Oncol. 2019;15 Suppl 6:5-7.
Tsang, M. W. (2019). Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report. Asia-Pacific Journal of Clinical Oncology, 15 Suppl 6, 5-7. https://doi.org/10.1111/ajco.13246
Tsang MW. Osimertinib 160 Mg Daily for Advanced Non-small Cell Lung Cancer With Leptomeningeal Metastasis: a Case Report. Asia Pac J Clin Oncol. 2019;15 Suppl 6:5-7. PubMed PMID: 31642175.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report. A1 - Tsang,Maverick Wai-Kong, Y1 - 2019/10/23/ PY - 2019/10/24/pubmed PY - 2020/1/14/medline PY - 2019/10/24/entrez KW - epidermal growth factor receptor KW - leptomeningeal carcinomatosis KW - metastasis KW - molecular targeted therapy KW - tyrosine kinase inhibitor SP - 5 EP - 7 JF - Asia-Pacific journal of clinical oncology JO - Asia Pac J Clin Oncol VL - 15 Suppl 6 N2 - Advanced non-small cell lung cancer (NSCLC) with leptomeningeal metastases (LM) is associated with a dismal prognosis of typically 3-9 months. In preclinical and clinical studies, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib has demonstrated activity in the central nervous system (CNS), and studies are ongoing. We report here a case of osimertinib used at 160 mg once daily in a heavily pretreated patient with EGFR exon 20 T790M-negative advanced NSCLC with LM to achieve a partial response, including shrinkage of the LM, for up to 12 months until further progression. The case suggests the feasibility of using osimertinib at a twofold standard dose to treat CNS metastases, irrespective of the T790M mutation status. SN - 1743-7563 UR - https://www.unboundmedicine.com/medline/citation/31642175/Osimertinib_160_mg_daily_for_advanced_non_small_cell_lung_cancer_with_leptomeningeal_metastasis:_A_case_report_ L2 - https://doi.org/10.1111/ajco.13246 DB - PRIME DP - Unbound Medicine ER -